Clinical Trials Browser

Phase 1 × avelumab × Tumor-Agnostic × Clear all

NCT05396833 2026-02-19

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT03724890 2025-04-10

Study of Avelumab-M3814 Combinations

Phase 1 Completed

57 enrolled 56 charts

Neoplasms